Best Treatment Approach for Crohn's Disease Episodes

Treatment Selection Based on Disease Severity

The European Crohn's and Colitis Organisation recommends biologic therapies, such as anti-TNF agents, vedolizumab, or ustekinumab, as the most effective treatment options for moderate to severe Crohn's disease episodes, with the choice depending on disease characteristics, prior treatment response, and patient factors 1, 2, 3
Budesonide 9 mg daily is the preferred initial treatment for mild to moderate Crohn's disease, particularly for ileal or ileocecal disease, as it has fewer side effects than systemic corticosteroids 4
Systemic corticosteroids may be needed for more widespread disease or when budesonide is insufficient, according to the British Society of Gastroenterology 5

The American Gastroenterological Association recommends metronidazole 400 mg three times daily and/or ciprofloxacin 500 mg twice daily as appropriate first-line treatments for simple perianal fistulae 5
Azathioprine (1.5–2.5 mg/kg/day) or mercaptopurine (0.75–1.5 mg/kg/day) are effective for simple perianal fistulae when antibiotics are insufficient, as stated by the European Crohn's and Colitis Organisation 5
Infliximab should be reserved for patients with perianal or enterocutaneous fistulae refractory to other treatments, according to the American Gastroenterological Association 5, 6

The European Crohn's and Colitis Organisation strongly recommends maintenance with anti-TNF agents for patients who achieved remission with these agents 1, 7
Vedolizumab (300 mg IV every 8 weeks) is effective for maintaining clinical remission, with a response rate of 39.0% vs 21.6% with placebo at week 52, as reported by the American Gastroenterological Association 1, 7
Ustekinumab maintains clinical remission in 51% of patients over 44 weeks compared to 35.9% with placebo, according to the European Crohn's and Colitis Organisation 1, 7

Regular monitoring using objective markers, such as endoscopy, C-reactive protein, fecal calprotectin, and imaging, is essential to assess disease activity and treatment response, as recommended by the British Society of Gastroenterology 4

Mesalazine has limited benefit in Crohn's disease and is ineffective at doses below 2 g/day, according to the European Crohn's and Colitis Organisation 5
Smoking cessation is probably the most important factor in maintaining remission and should be strongly encouraged, as stated by the American Gastroenterological Association 5